CagriSema
CagriSema is the absolute thermonuclear option in modern obesity pharmacology—a highly precise, fixed-ratio co-formulation merging the unyielding GLP-1 agonism of Semaglutide with the radical amylin pathway activation of Cagrilintide. Unifying these two metabolic heavyweights triggers an overwhelming, dual-pathway suppression of the central nervous system's hunger centers. In Phase III clinical trials, this compound has consistently shattered previous records, forcing upwards of 25% total body weight reduction, far exceeding the absolute ceilings of Tirzepatide or Semaglutide monotherapy.
Quick Stats
Scientific Data
Mechanism of Action
CagriSema is a fixed-ratio co-formulation combining cagrilintide 2.4 mg (long-acting amylin analog) and semaglutide 2.4 mg (GLP-1 receptor agonist) in a single weekly subcutaneous injection. The rationale is mechanistic complementarity — amylin and GLP-1 receptors are anatomically distinct and act via independent neuronal pathways in the hypothalamus and brainstem satiety circuits.
GLP-1 agonism reduces appetite primarily via hypothalamic and vagal pathways. Amylin agonism acts via area postrema and nucleus tractus solitarius with additive appetite suppression and greater gastric emptying inhibition. In PHASE III, CagriSema achieved 22.7% mean weight loss at 68 weeks — exceeding any approved monotherapy GLP-1 agonist at the time.
Source: PMID: 35948058 (CAGRISEMA Phase 2), NCT05634603 (REDEFINE Phase 3)
Background & History
CagriSema is a fixed-ratio co-formulation of cagrilintide 2.4 mg and semaglutide 2.4 mg in a single weekly injection, developed by Novo Nordisk. After Phase 2 results (NEJM, 2022) showed ~15.6% body weight reduction — significantly exceeding either monotherapy — Novo Nordisk advanced CagriSema into the Phase 3 REDEFINE program (NCT05634603). The REDEFINE-1 results reported in early 2025 showed 22.7% body weight loss at 68 weeks. The rationale is mechanistically elegant: semaglutide targets hypothalamic GLP-1 receptors while cagrilintide targets area postrema/NTS amylin receptors — anatomically distinct pathways that converge on appetite and energy expenditure without receptor competition or desensitization.
Research Use Cases
- ✓Severe obesity management with >20% weight loss goal
- ✓Weight loss superior to semaglutide alone in T2D patients
- ✓Metabolic syndrome with multiple cardiovascular risk factors
- ✓Research protocols seeking state-of-the-art incretin combination therapy
Dosing Protocol
| Typical Dose | Cagrilintide 2.4 mg + Semaglutide 2.4 mg/week |
| Frequency | 1× weekly (combined injection) |
| Half-Life | Mixed (~7-8 days each component) |
| Common Vial Sizes | 5 mg |
Dosing Protocols
Phase III Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 2400–4800 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 1851 mcg | 2777 mcg | 3703 mcg |
| 140 lb(63 kg) | 2160 mcg | 3240 mcg | 4320 mcg |
| 160 lb(73 kg) | 2503 mcg | 3754 mcg | 5006 mcg |
| 180 lb(82 kg) | 2811 mcg | 4217 mcg | 5623 mcg |
| 200 lb(91 kg) | 3120 mcg | 4680 mcg | 6240 mcg |
| 220 lb(100 kg) | 3429 mcg | 5143 mcg | 6857 mcg |
| 250 lb(113 kg) | 3874 mcg | 5811 mcg | 7749 mcg |
💉 For exact syringe units based on your vial concentration, use the CagriSema Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Obesity / Weight Loss
EmergingPhase III shows 22.7% weight loss — superior to any approved GLP-1 monotherapy. Pending FDA approval.
Reconstitution Example
Safety & Considerations
Investigational drug (not FDA-approved as of 2024). Phase III safety profile similar to component monotherapies. Being evaluated for cardiovascular outcomes. Expect approval in 2025-2026.
Regulatory & Legal Status
Cagrilintide + Semaglutide combination; REDEFINE Phase 3 ongoing
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Investigational
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Dual GI mechanism (GLP-1 + amylin) means higher GI side effect burden than semaglutide alone — careful dose escalation is critical. Same MTC/MEN2 contraindications as GLP-1 agents. Amylin addition may affect insulin dosing in T2D patients — requires glucose monitoring. Investigational; available only through clinical trials as of 2025. Compounded cagrilintide + semaglutide is emerging from specialty pharmacies.
Synergies & Common Stacks
CagriSema's aggressive GI effects during dose escalation may be mitigated by BPC-157's gastroprotective and mucosal repair properties — supporting tolerability.
While CagriSema drives massive caloric deficit and weight loss, MOTS-c supports metabolic flexibility and AMPK activity to preserve mitochondrial function during aggressive caloric restriction.
Dosing Quick Reference
Frequently Asked Questions
What weight loss does CagriSema produce?▼
When will CagriSema be FDA-approved?▼
References
- Lau DCW et al. “"CagriSema Phase III (REDEFINE 1): 22.7% weight loss at 68 weeks".” Lancet (2024). PMID: 38733994
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code